Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma – Pivotal phase 3 CELESTIAL trial results, including additional subset analyses, to be presented during oral session on Friday, January 19 at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO-GI) – – Exelixis to submit supplemental New Drug Application to U.S. Food and Drug Administration (FDA) in the first quarter of 2018 – https://www.businesswire.com/news/home/20180116006839/en/Exelixis-Ipsen-Announce-Phase-3-Trial-Results